PARIS, June 12 (Reuters) – France’s Sanofi said on
Sunday that two late-stage Phase III clinical trials of its
LixiLan diabetes drug had met their targets, readying it for
approval in the United…
The post Sanofi says LixiLan diabetes drug trials meet targets appeared first on NASDAQ.